MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/17562864261458516

Медицинская библиотека · Therapeutic advances in neurological disorders · 2026

Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers.

Pawlitzki Marc, Kirschner Patricia, Masanneck Lars, Hagler Ramona, Meier Elias, Vach Marius, Inojosa Hernan, Ziemssen Tjalf, Ivan Vivien Lorena, More Shammi, Patil Kaustubh, Firouzi-Memarpuri Parnian, Caspers Julian, Repple Jonathan, Dannlowski Udo, Khalil Michael, Meuth Sven G, Rubbert Christian

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Multiple sclerosis (MS) is influenced by age-related brain alterations and affects cellular aging mechanisms. Machine-learning models can estimate brain-predicted age from magnetic resonance imaging (MRI) to quantify these aging-related changes.

OBJECTIVES

This study examines whether the difference between predicted and chronological age (BrainAGE) relates to clinical disability and biomarkers of neuro-axonal injury in MS.

DESIGN

This study analyzed brain-predicted age from structural 3D T1-weighted MRI in 82 patients with relapsing MS enrolled in three prospective clinical trials and 30 healthy controls.

METHODS

BrainAGE, calculated as MRI-predicted minus chronological age, was correlated with the Expanded Disability Status Scale (EDSS), MS Functional Composite subtests, and serum neurofilament light chain and glial fibrillary acidic protein.

RESULTS

The mean chronological age of patients and healthy controls included in this study was 39.2 and 40.9 years, respectively. Patients with MS (n = 82) showed a higher BrainAGE (6.48 ± 6.83 years) than controls (n = 30; 0.69 ± 6.5 years; p = 0.0002). BrainAGE increased stepwise from controls to patients with EDSS < 3 and EDSS ⩾3 (p < 0.0001). Higher BrainAGE correlated with worse 9-Hole Peg Test (9HPT, ρ = 0.34, p = 0.002) and Timed 25-Foot Walk performance (T25FW, ρ = 0.23, p = 0.043), but not with serum neurofilament light chain (p = 0.68) or glial fibrillary acidic protein (p = 0.33). In multivariable regression models adjusting for chronological age, sex, disease duration, and disease-modifying therapy, BrainAGE remained significantly associated with EDSS, 9HPT, and T25FW performance. sNfL and sGFAP remained nonsignificant after adjustment.

CONCLUSION

Our findings suggest that BrainAGE and serum biomarkers capture complementary aspects of MS pathology, supporting a multimodal approach to assess disease progression.

TRIAL REGISTRATION: ClinicalTrials.gov ID: SATURATE: NCT05701423, 360PMS: NCT06501950, SAFEGUIDE-MS: NCT06461481.

Для цитирования: Pawlitzki Marc, Kirschner Patricia, Masanneck Lars, Hagler Ramona, Meier Elias, Vach Marius, Inojosa Hernan, Ziemssen Tjalf, Ivan Vivien Lorena, More Shammi, Patil Kaustubh, Firouzi-Memarpuri Parnian, Caspers Julian, Repple Jonathan, Dannlowski Udo, Khalil Michael, Meuth Sven G, Rubbert Christian. Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers.. Therapeutic advances in neurological disorders. 2026. DOI: 10.1177/17562864261458516.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.